Navigation Links
ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
Date:1/5/2011

IRVINE, Calif., Jan. 5, 2011 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today, during its previously announced guidance call, that it expects to achieve its 2010 net revenues guidance of $147 million to $167 million with anticipated, unaudited net revenues in the mid-$150 million range.  The company also said it expects to exceed $1 million in unaudited net income in 2010, before any warrant expense.

President and Chief Executive Officer Vicente Anido, Jr., Ph.D., said, "ISTA has established itself as a successful pharmaceutical developer, an aggressive competitor and a fast-growing, profitable specialty pharmaceutical company. We've managed effectively through the company's start-up phase, obtained FDA approval to market five drugs in just six years, and established a formidable sales force calling on ophthalmologists, optometrists and allergists.  In 2010, we achieved revenue growth of about 40% as compared to 2009, while delivering our first year of profitability."

2011 Financial Outlook in Detail

On today's guidance call, Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail reiterated the company's 2011 revenues guidance provided on the third quarter 2010 earnings call and gave additional detail on revenue, expenses, income and cash.  ISTA expects:  

  • 2011 net revenues will be approximately $175 million to $190 million.
  • 2011 gross margins will be in the 75% to 77% range.
  • 2011 R&D expenses will be 18% to 22% of net revenues.
  • 2011 SG&A expenses will be 44% to 48% of net revenues.
  • 2011 operating income will be $13 million to $16 million.
  • 2011 net income will be $5 million to $8 million, or fully diluted earnings per share of $0.11 to $0.18, assuming 44 million fully diluted shares and
    '/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... VILLAGE, Nev., Nov. 2 PDL BioPharma, Inc. (PDL) ... on its previously disclosed $300 million securitization transaction intended ... royalties. Morgan Stanley & Co. Incorporated acted as ... terms of the securitization transaction, PDL sold to QHP ...
... Nov. 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... 30, 2009 on Monday, November 9, 2009, following the close of ... conference call at 5:00 p.m. Eastern Time on the same day ... call will be available for two weeks following the event. ...
Cached Medicine Technology:PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:5/30/2015)... 2015 This year the National ... Horizons to offer one of the most diverse perspectives ... successful practices to diagnose, treat and manage patients with ... Horizons Conference is Interaction with Multidisciplinary Healthcare Professionals ... Needs of Patients with COPD," said Brian W. Carlin, ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Venus Viva ... acne scars, large pores, deep wrinkles, stretch marks, pigmentation ... medical professional, such as Dr. F. Victor Rueckl of ... the clinical trials in Las Vegas. This body image ... into a system that delivers proven results through a ...
(Date:5/29/2015)... “In the current environment of ... regulations, we provide education that will help practitioners ... suffering from pain, within the boundaries of the ... of rehabilitation medicine and President/Medical Director of the ... , A new flight of PAINWeekEnd Regional Conferences ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 What does ... The Denver Foundation, community comes together to plant gardens, ... build neighborhoods and awareness of critical issues. Community invites ... Denver and beyond. , "What Community Does" was commissioned ... foundation in Colorado, and released during the foundation’s Annual ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The third ... The event, now closed to new registration, starts outside ... This exciting competitive running event demonstrates the power ... create a public benefit – in this case, historic ... views around the famed Ocean Drive and passes by ...
Breaking Medicine News(10 mins):Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3
... who had "Tommy John" elbow reconstruction surgery were able to ... to a study released today at the 2008 American Orthopaedic ... Grande Lakes. While reassuring to athletes, the study authors find ... surgery, alarming. , "Before 1997 this surgery was performed on ...
... (CDH) of Winfield, Ill. has been ranked #47 in ... accessible today online,at http://www.usnews.com/besthospitals and on sale ... 5,453 hospitals reviewed, only 170 medical centers,nationwide ranked high ... listed in one or more of the 16 specialties., ...
... 11 In a letter to the,Senate, forty-five ... to address critical shortfalls in legislation that would,reauthorize ... the Senate,poised to vote on a five-year, $50 ... to "both set and correct policies based,on evidence ...
... Calif., July 11 A,democratic process involving several SEIU ... with hearings to determine the best way to unite,long-term ... greatest strength,to win for their families and the clients ... a thorough, open, and democratic,discussion to make sure that ...
... no difference, study finds , , FRIDAY, July 11 (HealthDay ... developing breast cancer do not seem to improve even ... the disease, a new report says. , Scientists have ... small but statistically significant increase in the risk of ...
... Zen at Zoe's Garden, a new Baltimore wellness center offering massage ... in Fells Point. , ... Baltimore, MD (PRWEB) July ... wellness center offering massage therapy, acupuncture, yoga instruction , ...
Cached Medicine News:Health News:Dramatic increase in 'Tommy John' surgery in young patients cause for concern 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 2Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 4Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 5Health News:Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer 2Health News:Baltimore Wellness Center "Zen at Zoe's Garden" Launches in Baltimore's Fells Point 2
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: